Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Trevi Therapeutics Inc

TRVI ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$18.46

▲ +1.71%

Market Cap $2.63B · Vol 387.98K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.63B

Mid Cap

Div Yield

N/A

EPS Growth

-50.00%

YoY

RSI (14)

54.17

Momentum

Beta

1.06

vs Market

52W High

$20.14

8.34% below

52W Low

$6.94

165.99% above

Volume

387.98K

Avg 601.09K

P/B

8.77

Price-to-book

ROE

-30.23%

Return on equity

Free Float

90.66%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Trevi Therapeutics Inc (TRVI) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TRVI pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.27%

+3.07%

+22.41%

+77.50%

YTD

+47.44%

+146.46%

+662.81%

+827.64%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-42,759,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-30.23%
ROA · ROIC	-28.14% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	8.77
P/FCF	N/A
EPS Growth	-50.00%
Outstanding Shares	142.48M

Technical Indicators

50-Day SMA	$17.25
200-Day SMA	$13.54
RSI (14)	54.17
Beta	1.06
52-Week High	$20.14
52-Week Low	$6.94

Volume Today	387.98K
Avg Daily Volume (30D)	601.09K
Relative Volume	0.65x
Volatility (10D)	35.31
Volatility (30D)	74.35
Free Float	90.66%

Analyst Consensus

BUY

Current Price $18.46

Mean Target $29.50

52W Low$6.94 52W High$20.14

Current

Target

$6.94 $20.14

Current Analyst target

+59.80% upside potential · 12 analysts

Identifiers

ExchangeNasdaq

FIGIBBG003QGQRC8

ISINUS89532M1018

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.